Article Text

PDF

Inflammatory bowel disease I
PMO-242 The IBD-control questionnaire: development and psychometric validation of a tool for capturing disease control from the patient perspective for use in routine care
  1. C Ormerod1,
  2. D Shackcloth1,
  3. M Harrison1,
  4. E Brown1,
  5. K Bodger2
  1. 1Digestive Diseases Centre, Aintree University Hospital, Liverpool, UK
  2. 2Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Abstract

Introduction Although a range of disease activity measures and QoL questionnaires is available for IBD, none has found a place in routine clinical practice. This project aimed to develop a tool for capturing disease control from the patient's perspective with measurement properties appropriate for routine clinical practice.

Methods Phase I: Systematic review of existing PROMS, patient focus groups and a steering group to define domains and items for the “IBD-Control”. Instrument comprises 13 questions items plus a visual analogue scale (VAS, 0–100) for overall control. Phase II: Prospective validation, patient completion of IBD-Control, QoL questionnaire (UK-IBD-Q), EuroQol (EQ5D), Hospital Anxiety & Depression Score (HADS); clinician assessment (blinded to questionnaire) recording disease activity (Harvey Bradshaw Index, HBI; or Simple Clinical Colitis Activity Index, SCCAI), global clinician assessment (remission; mild; moderate; severe), Montreal Classification, treatment history. Ongoing longitudinal survey (serial questionnaires).

Results 194/200 returned baseline surveys (CD, n=107; UC, n=87). Study population (CD, UC): Age (mean): 41; 48 yrs. Disease duration (mean): 10.5; 10.7 yrs. Prev. Surgery (%): 50%; 3.4%. Immunosuppressants (%): 49.5%; 27.6%. Biologics (%): 22.4%; 8.0%. Disease activity (mean [SD] HBI; SCCAI): 5 [5]; 4 [3]. Measurement properties of IBD-Control: Completion time (mean [SD]): 1 min 15 s [25s]; Internal consistency: Cronbach's α for all 13 items: 0.838; for sub-group of 8 questions (IBD-Control-8): 0.841. Strong correlation between IBD-Control-8 sub-score and IBD-Control-VAS (r=0.79). Test-retest reliability for stable patients (Baseline vs 2 week repeat, no change): IBD-Control-8, 15.8 vs 15.6; p=0.73; IBD-Control-VAS, 65.5 vs 68.0, p=0.33. Validity: Moderate-to-strong correlations between IBD-Control-8 subscore and IBD-Control-VAS vs disease activity, UK-IBD-Q and global health state (utility) with r values 0.56 to 0.84. Discriminant validity (mean scores for remission, mild, moderate, severe): ANOVA p<0.01. Sensitivity to change: (analysis of first 53 follow-ups): No significant changes for stable patients; moderate-to-large responsiveness statistics for IBD-Control-8 and IBD-Control-VAS: (Effect sizes: 0.4–1.6).

Conclusion The IBD-Control shows promise as a rapid (<2 min), reliable, valid and sensitive instrument for measuring overall disease control from the patients perspective. Unlike existing PROMS, its ease-of-use and generic applicability make it a candidate for use in routine practice as a decision-support tool for patients and clinicians.

Competing interests C Ormerod: None declared, D Shackcloth: Grant/Research Support from: Abbott Laboratories Ltd, M Harrison: None declared, E Brown: None declared, K Bodger: Grant/Research Support from: Abbott Laboratories Ltd.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.